ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Biology Societies Recomend 15% Funding Increase for NIH

February 12, 1999

Virus Program Changes reviews Subcommittee Report Set Fro June

November 23, 1974

Mihich Subcommittee Recommendations For Augmenting Agents In BRMP Described

December 7, 1979

Funding Opportunities: RFA Available: Teams For Molecular Target Assessment

November 26, 1999

Radiation Oncology To Become Crowded, ACR Warns Physicians

December 15, 1995

RFPS, RFAs Available

September 23, 1994